AASLD – The Liver Meeting 2021

infohep news

• Hepatitis delta

  Bulevirtide for hepatitis D proves effective in real-world studies

  Liz Highleyman / 25 January 2022

  The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load and improved liver enzyme levels in real-world studies in France and Austria, according to findings presented ...

• Hepatocellular carcinoma (HCC)

  Some people remain at risk for liver cancer despite hepatitis C treatment

  Liz Highleyman / 22 December 2021

  Some people with liver cirrhosis remain at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C treatment, according to study results presented at The Liver Meeting. Not achieving a cure was the biggest ...

• Treatment for previous non-responders & relapsers

  Three-drug regimen plus ribavirin cures the hardest-to-treat hepatitis C patients

  Keith Alcorn / 08 December 2021

  People who have experienced failure of multiple courses of direct-acting antiviral treatment can be cured of hepatitis C with a combination of three direct-acting antivirals plus ribavirin, a review of heavily treatment-experienced patients ...

• Coronavirus

  COVID-19 vaccine protection is ‘lower and slower’ in people with cirrhosis

  Keith Alcorn / 22 November 2021

  People with cirrhosis of the liver may take longer to achieve protection from SARS-CoV-2 and severe COVID-19 after vaccination, according to large studies in the United States and Chile, presented earlier this month ...

• Coronavirus

  People with liver cirrhosis have weaker responses to the Pfizer and Moderna SARS-CoV-2 vaccines

  Keith Alcorn / 16 November 2021

  People with cirrhosis of the liver had delayed and suboptimal responses to the Pfizer or Moderna SARS-CoV-2 vaccines compared to healthy adults, an Italian study has found. People with decompensated cirrhosis had significantly ...

• Coronavirus

  Treatment for hepatitis B and C fell in 2020 due to COVID-19, global survey finds

  Keith Alcorn / 16 November 2021

  Viral hepatitis tests and treatment declined significantly during 2020 as a consequence of the COVID-19 pandemic, a survey of 31 liver centres on five continents has shown. The decline in testing and ...

• Hepatitis C elimination

  Hepatitis C elimination: less than 25% of people with hepatitis C diagnosed globally

  Keith Alcorn / 15 November 2021

  The global prevalence of hepatitis C has declined since 2015, partly due to scale-up of direct-acting antiviral treatment, but fewer than one in four people with hepatitis C has been diagnosed, ...

• Hepatitis C elimination

  Hepatitis C treatment in US declined from 2015 to 2020

  Liz Highleyman / 14 November 2021

  From a height of more than 164,000 in 2015, the number of people treated with direct-acting antiviral (DAA) therapy for hepatitis C has steadily declined, reaching a low point during the COVID-19 pandemic, ...